University Communication, February 17, 2020
Celerion expands clinical research to Nebraska Innovation Campus
Nebraska Innovation Campus has announced a new partner. Dan Duncan, NIC’s executive director, said Celerion is moving into space on the first level of the Rise Building, NIC’s newest building, this month.
Celerion has been conducting clinical research studies for more than 50 years in Lincoln for pharmaceutical and biotechnology companies around the world. Its work involves investigational medicines currently in research and development, used to treat a wide variety of illnesses and conditions.
An open house being planned for March will provide Celerion staff the opportunity to learn about ways to partner with faculty and students and allow visitors to learn more about the drug-development process and pharmaceutical research opportunities at Celerion.
“Celerion is a great long-term fit for NIC,” Duncan said. “Their clinical research expertise will be invaluable as the Nebraska Food for Health Center continues to develop and companies in the Biotech Connector mature.”
Phil Bach, vice president for global clinical research at Celerion, said the company is pleased to announce its expansion to NIC.
“We’re excited to take this next step to further our clients’ goals for drug development,” he said. “This space will allow us to partner with top-notch students, faculty and entrepreneurs at NIC and collaborate at the forefront of the biotechnology hub in Nebraska.”
The new location at NIC demonstrates Celerion’s commitment to innovation and excellence in clinical research, Bach said.
“We are committed to scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug-development path,” he said. “Establishing a partnership at NIC will allow us to provide new service avenues as clients look to bring their drugs to the market.”
NIC is a campus designed to facilitate new and in-depth partnerships between the university and private-sector businesses. At full build-out, NIC will be a 2.2-million-square-foot campus with uniquely designed buildings and amenities that inspire creative activity and engagement, transforming ideas into global innovation. Learn more.
Tetrad Property Group is the private-sector development partner for NIC. Tetrad provides a full range of development services for the campus, including master planning, construction management, leasing and property management. Learn more.
Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives clients the confidence to make fast, accurate decisions about their drug-development path. For 50 years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic and pharmacodynamics studies in highly controlled clinic environments. These include first-in-human dose escalation, drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies, as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. Celerion offers feasibility, data management, biostatistics, clinical monitoring and bioanalytical services. The company’s founding mission is to help clients get drugs to market quickly so they can help people in need around the world. Learn more.